McLoughlin Margaret
Known title: DirectorCIK: 0001770823
McLoughlin Margaret's purchase track record
McLoughlin Margaret has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/8/2023 | QNCX | $10K | -25.3% | +5.7% | +10.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| QNCX | ▲ Buy | Open Market | 8,000 | $10K | 8/8/2023 | View on chart |
| QNCX | ▲ Buy | Option Exercise | 1,000 | $17K | 10/8/2021 | View on chart |
| QNCX | ▼ Sell | Open Market | 1,000 | $89K | 10/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Quince Therapeutics LAM-001 Progress; Analyst Targets $70
Quince Therapeutics reported progress on its LAM-001 program for pulmonary hypertension and bronchiolitis obliterans syndrome. A new analyst coverage was launched with a buy rating and a $70 price target. The company’s stock is trading near its 12‑touch support level of $17.70 and shows a moderate RSI of 55.9, indicating balanced momentum.
Quince Therapeutics LAM-001 Progress; Analyst Targets $70. Quince Therapeutics reported progress on its LAM-001 program for pulmonary hypertension and bronchiolitis obliterans syndrome. A new analyst coverage was launched with a buy rating and a $70 price target. The company’s stock is trading near its 12‑touch support level of $17.70 and shows a moderate RSI of 55.9, indicating balanced momentum.